ClinicalTrials.gg
CompletedNCT01957176Updated Dec 30, 2022Results posted

A Rollover Study to Provide Continued Treatment With Eltrombopag

A Phase 4 interventional study of Eltrombopag (ELT) in Thrombocytopaenia, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.

Enrollment
40th of 53
22 · median 40
Started
2013
with 5 others
Phase 4
3 of 53
none open now
Registered
39th of 53
by date
Lead sponsor
6 of 53
Novartis Pharmaceuticals

Among the 53 studies testing eltrombopag in Thrombocytopenia, this one is the 40th largest by enrollment, is one of 6 that started in 2013, is one of 3 in phase 4, and was the 39th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing eltrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

The objective of this study was to provide continued treatment with eltrombopag for subjects who were participating in a Novartis-sponsored investigational study with eltrombopag (parent studies 114968/ASPIRE (NCT01440374), PMA112509 (NCT00903422), and TRA105325/EXTEND (NCT00351468), receiving clinical benefit without unacceptable toxicity and to collect long-term safety data.

Read the detailed description

This Phase IV, multicenter, non-randomized, open-label, uncontrolled, rollover study was designed to provide continued access to eltrombopag to eligible subjects. As this study was a rollover study, the subjects were enrolled into this study from the parent studies.

There were 3 cohorts in this study:

Cohort A: Adult subjects who have completed study treatment with eltrombopag during their participation in a parent study for MDS/AML (i.e., 114968/ASPIRE and PMA112509).

Cohort B: Adult subjects who have completed study treatment with eltrombopag during their participation in a parent study for ITP (i.e., TRA105325/EXTEND).

Cohort C: Pediatric subjects who have completed study treatment with eltrombopag during their participation in a parent study for ITP. Once a subject turned 18 years of age, they might remain in the study and follow the Cohort B procedures. No pediatric subjects were enrolled in this cohort/study.

The study consisted of a transition visit, study treatment visits, and a follow-up visit. Subjects in Cohort A and Cohort B completed the Transition visit assessments and then returned for their next schedule visit as per the Visit schedule. In the study treatment visit, subjects received a starting dose of eltrombopag at the same dose and administration that they were receiving at the time of their last study treatment visit in the parent study.

Safety was evaluated through physical examinations, clinical laboratory tests, and monitoring of adverse events. Additional safety assessments were done as per standard of care and/or when medically indicated.

Assessment of clinical benefit was performed throughout the study using local standard of care as determined by the Investigator to determine continued study participation and treatment with eltrombopag. Only subjects considered by the Investigator to be receiving clinical benefit without unacceptable toxicity may continue on study treatment. Once treatment with eltrombopag was permanently discontinued, the subject would attend the follow-up visit.

03

Conditions studied

  • Thrombocytopaenia

Keywords

  • myelodysplastic syndromes
  • thrombocytopenia
  • acute myeloid leukemia
  • idiopathic thrombocytopenic purpura
  • Eltrombopag
  • pediatrics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written has been obtained from the subject (or subject's legally acceptable representative) prior to performance of any study-specific procedure.
  • The subject is participating in a GSK sponsored study of eltrombopag (parent study) within the past 28 days and is receiving clinical benefit without unacceptable toxicity as determined by the investigator.
  • Subjects with a \<450 millisecond (msec) or \<480 msec for subjects with bundle branch block. The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB), Fridericia's formula (QTcF) or another method, machine or manual overread. For subject eligibility and withdrawal QTcF will be used. For purposes of data analysis, QTcF will be used. The QTc should be based on single or averaged QTc values of triplicate (ECGs) obtained over a brief recording period.
  • Women must be either of non-child bearing potential or women with and men with must be willing to practice acceptable methods of during the study.
  • Women of childbearing potential must have a negative serum pregnancy test within 14 days of the first dose of study treatment and agree to use effective contraception, during the study and for 4 weeks following the last dose of study treatment.
  • Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of first dose until 16 weeks after the last dose of study treatment.
  • In France, a subject will be eligible for inclusion in this study only if either affiliated to, or a beneficiary of, a social security category.

Exclusion criteria

Exclusion Criteria:

  • Permanent discontinuation of eltrombopag in the parent study based upon the study treatment discontinuation or study withdrawal criteria from the parent study. Subjects who permanently discontinued treatment because they completed all study related treatments remain eligible.
  • The subject is pregnant or a lactating female.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions at the time of transition to this study that could interfere with subject's safety, obtaining or compliance with the study procedures, in the opinion of the investigator or GSK Medical Monitor.
  • French subjects: The French subject has participated in any study using an drug during the previous 30 days, with the exception of eltrombopag, in the parent study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Cohort A (Myelodysplastic syndrome (MDS)/ Acute myeloid leukemia (AML) adult subjects)

    All subjects in this cohort received eltrombopag (ELT) at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 50 to 300 mg once daily (OD) for subjects of non-East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e., Japanese, Chinese, Taiwanese, Thai and Korean) were 25 to 150 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.

    Drug: Eltrombopag (ELT)

  • Experimental
    Cohort B (Idiopathic thrombocytopenic purpura (ITP) adult subjects)

    All subjects in this cohort received ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 12.5 to 75 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.

    Drug: Eltrombopag (ELT)

  • Experimental
    Cohort C (Idiopathic thrombocytopenic purpura (ITP) pediatric subjects)

    All subjects in this cohort received ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 12.5 to 75 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.

    Drug: Eltrombopag (ELT)

Interventions

  • Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.

    Also known as: SB-497115

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    The distribution of adverse events was done via the analysis of frequencies for Adverse Events (AEs) and Serious Adverse Events (SAEs), through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis performed.

    Time frame: From the time of transition visit until 30 days after last dose of study treatment, assessed up to approximately 100 months.

07

Results

Posted Dec 30, 2022

Participant flow

22 subjects were enrolled in 14 centers in 12 countries (Belgium, China, France, Greece, Hong Kong, Ireland, Korea, Republic of., Netherlands, Peru, Poland, Romania, Tunisia).

Participant flow — Overall Study
MilestoneCohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects)Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects)
Started814
Completed313
Not completed51
Withdrew: Adverse event20
Withdrew: Physician decision21
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

The distribution of adverse events was done via the analysis of frequencies for Adverse Events (AEs) and Serious Adverse Events (SAEs), through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis performed.

Time frame:
From the time of transition visit until 30 days after last dose of study treatment, assessed up to approximately 100 months.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsCohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects)Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects)
Adverse Events (AEs)712
Serious Adverse Events (SAEs)67

Adverse events

Collected over From the time of transition visit until 30 days after last dose of study treatment, assessed up to approximately 100 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects)3/8 (37.5%)6/8 (75%)7/8 (87.5%)
Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects)2/14 (14.3%)7/14 (50%)12/14 (85.7%)
All Subjects5/22 (22.7%)13/22 (59.1%)19/22 (86.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventCohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects)Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects)All Subjects
SepsisInfections and infestations2/80/142/22
Atrial fibrillationCardiac disorders1/80/141/22
AscitesGastrointestinal disorders1/80/141/22
Multiple organ dysfunction syndromeGeneral disorders1/80/141/22
PyrexiaGeneral disorders1/80/141/22
Cholecystitis acuteHepatobiliary disorders1/80/141/22
PneumoniaInfections and infestations1/81/142/22
Alanine aminotransferase increasedInvestigations1/80/141/22
HypernatraemiaMetabolism and nutrition disorders1/80/141/22
Subdural hygromaNervous system disorders1/80/141/22
Most frequent other events
Showing 10 of 166
Most frequent other events
EventCohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects)Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects)All Subjects
PyrexiaGeneral disorders4/83/147/22
Oedema peripheralGeneral disorders3/81/144/22
EosinophiliaBlood and lymphatic system disorders0/85/145/22
Upper respiratory tract infectionInfections and infestations1/85/146/22
ArthralgiaMusculoskeletal and connective tissue disorders1/85/146/22
HeadacheNervous system disorders1/85/146/22
DiarrhoeaGastrointestinal disorders1/84/145/22
HypertensionVascular disorders1/84/145/22
AnaemiaBlood and lymphatic system disorders2/82/144/22
FatigueGeneral disorders2/80/142/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects)Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects)Total
Mean73.8 ± 7.5759.5 ± 13.1864.7 ± 13.26
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects)Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects)Total
Female31215
Male527
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A (Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukemia (AML) Adult Subjects)Cohort B (Idiopathic Thrombocytopenic Purpura (ITP) Adult Subjects)Total
American Indian or Alaskan Native022
Asian - East Asian Heritage156
White - Arabic/North African Heritage066
White - White/Caucasian/European Heritage718
08

Study locations

13 sites
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Paris Cedex 12, 75571, France
  • Novartis Investigative Site
    Athens, 11527, Greece
  • Novartis Investigative Site
    Heraklion, Crete, 71201, Greece
  • Novartis Investigative Site
    Shatin, Hong Kong
  • Novartis Investigative Site
    Tullamore, Ireland
  • Novartis Investigative Site
    Seoul, 02841, Korea, Republic of
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    San Isidro, Lima Lima 27, Peru
  • Novartis Investigative Site
    Chorzow, 41-500, Poland
  • Novartis Investigative Site
    Bucharest, 022328, Romania
  • Novartis Investigative Site
    Sousse, 4000, Tunisia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2013 to primary completion in Feb 2022, 100 months.

Results were first posted in Dec 2022, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2013
First posted
Oct 8, 2013
StartActual
Oct 15, 2013
Primary completionActual
Feb 23, 2022
CompletionActual
Feb 23, 2022
Results first posted
Dec 30, 2022
Last update
Dec 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01957176
Responsible party
Sponsor
First posted
Oct 8, 2013
Start date
Oct 15, 2013
Primary completion
Feb 23, 2022
Completion
Feb 23, 2022
Results posted
Dec 30, 2022
Last update
Dec 30, 2022

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion